28
5
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10287 |
ALK2-IN-2
|
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
ALK2-IN-2是一种强效且具有选择性激活素受体样激酶2(ALK2)的抑制剂(IC50:9 nM),对 ALK2的抑制作用比 ALK3高700倍。 | |||
T8108 |
Blu-782
ALK2-IN-1 |
ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
Blu-782 (ALK2-IN-1) 是一种激活素受体样激酶 2 (ALK2) 抑制剂 ( IC50 <10 nM)。 | |||
T39764 |
KER047
ALK2-IN-4 |
ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
KER047 (ALK2-IN-4) 是一种 ALK2 抑制剂,具有潜在 的抗癌活性,可用于研究非小细胞肺癌。 | |||
T40065 |
ALK2-IN-4 succinate
ALK2-IN-4 succinate |
Others | Others |
ALK2-IN-4 succinate is a robust and effective inhibitor of ALK2. | |||
T79020 |
ALK2-IN-5
|
Others | Others |
ALK2-IN-5为一种吡唑并嘧啶化合物,具有抑制ALK2及FGFR活性的作用。该抑制剂常用于癌症等疾病的研究,这些疾病与ALK2及/或FGFR的活性有关。 | |||
T1943 |
ML347
LDN 193719 |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
ML347 (LDN 193719) 是一种选择性的 ALK1/ALK2 抑制剂,它们的 IC50 分别为 46/32 nM,比对 ALK3 的抑制性高 300 倍。 | |||
T1944 |
LDN-214117
|
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
LDN214117 是一种高效的 ALK2 选择性抑制剂(IC50:22nM),也是一种 BMP6 抑制剂(IC50:100nM),对ALK5抑制力弱100倍。 | |||
T1900 |
LDN-212854
LDN212854,BMP Inhibitor III |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
LDN-212854 (BMP Inhibitor III) 是一种新型BMP 抑制剂,抑制 ALK2 的IC50=1.3 nM,比对ALK1,ALK3,ALK4和ALK5的抑制性高2,66,1641和7135倍。 | |||
T35694 |
OD36
OD 36,OD 36 hydrochloride,OD-36 |
ALK; RIP kinase | Angiogenesis; Apoptosis; NF-κB; Tyrosine Kinase/Adaptors |
OD36 是一种选择性强效 RIPK2 抑制剂,IC50 为 5.3 nM。OD36 可抑制 ALK2 信号传导和成骨分化(KD:37 nM),并能与 ALK2 激酶 ATP 袋有效结合。 | |||
T1977 |
Dorsomorphin
Compound C,BML-275 |
AMPK; Autophagy; TGF-beta/Smad | Autophagy; Chromatin/Epigenetic; PI3K/Akt/mTOR signaling; Stem Cells |
Dorsomorphin (BML-275) 是一种 AMPK 抑制剂 (Ki=109 nM),具有选择性和 ATP 竞争性。Dorsomorphin 可以抑制 BMP I 型受体 ALK2、ALK3 和 ALK6。Dorsomorphin 可诱导自噬,具有抗肿瘤活性。 | |||
T1935 |
LDN193189
LDN-193189,DM-3189,LDN 193189 |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
LDN193189 (DM-3189) 是一种 BMP I 型受体的选择性抑制剂,可以抑制 ALK2 和 ALK3 (IC50=5/30 nM),对 ALK4、ALK5 和 ALK7 的活性较弱。LDN193189 可以用于进行性骨化性纤维发育不良的研究。 | |||
T1942 |
DMH-1
DMH1 |
ALK; Autophagy; TGF-beta/Smad | Angiogenesis; Autophagy; Stem Cells; Tyrosine Kinase/Adaptors |
DMH-1 是一种选择性 BMP 抑制剂,对 ALK1、ALK2、ALK3和 ALK6的 IC50值分别为 27、107.9、<5和 47.6 nM。 | |||
T35348 |
LDN-193189 2HCl
LDN-193189 2HCl,DM-3189 2HCl |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
LDN-193189 2HCl (DM-3189 2HCl) 是一种选择性 BMP 信号抑制剂,对ALK1,ALK2,ALK3和ALK6有抑制作用,在激酶实验中显示的 IC50 分别为 0.8 nM、0.8 nM、5.3 nM 和 16.7 nM。LDN-193189 2HCl 在C2C12细胞中对BMP I 型受体ALK2和ALK3的转录活性有抑制作用,IC50分别为5 nM 和30 nM,作用于BMP 比作用于TGF-β选择性高200倍。 | |||
T1914 |
K02288
K 02288 |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
K 02288是骨形态发生蛋白 (BMP) I 型受体抑制剂,能够抑制 ALK1 (IC50:1.8nM)、ALK2 (IC50:1.1nM)、ALK6 (IC50:6.4nM)。对 ALK3 和 ALK6 的抑制稍弱,IC50在 5-34 nM 之间。 | |||
T6146 |
Dorsomorphin dihydrochloride
BML-275 2HCl,Compound C dihydrochloride,6-[4-[2-(1-哌啶基)乙氧基]苯基]-3-(4-吡啶基)吡唑并[1,5-A]嘧啶,Dorsomorphin (Compound C) 2HCl,Compound C 2HCl,BML-275 dihydrochloride |
AMPK; Autophagy; TGF-beta/Smad | Autophagy; Chromatin/Epigenetic; PI3K/Akt/mTOR signaling; Stem Cells |
Dorsomorphin dihydrochloride (BML-275 2HCl) 是一种 AMPK 抑制剂 (Ki=109 nM),具有选择性和 ATP 竞争性。Dorsomorphin dihydrochloride 可以抑制 BMP I 型受体 ALK2、ALK3 和 ALK6。Dorsomorphin dihydrochloride 可诱导自噬,具有抗肿瘤活性。 | |||
T6496 |
Vactosertib
TEW-7197,EW-7197 |
ALK; TGF-beta/Smad | Angiogenesis; Stem Cells; Tyrosine Kinase/Adaptors |
Vactosertib (EW-7197) 是有效的、具有 ATP 竞争性的、具有口服活性的激活素受体样激酶 5 (ALK5) 抑制剂(IC50:12.9 nM)。它还以纳摩尔浓度抑制 ALK2 和 ALK4 (IC50为 17.3 nM),表现出强大的抗转移活性和抗癌作用。 | |||
T61424 |
OD36 hydrochloride
OD 36 hydrochloride,OD-36 hydrochloride |
ALK; RIP kinase | Angiogenesis; Apoptosis; NF-κB; Tyrosine Kinase/Adaptors |
OD36 hydrochloride (OD-36 hydrochloride) 是一种强效的 RIPK2 抑制剂,IC50 为 5.3 nM。OD36 hydrochloride 是一种大环抑制剂,可与 ALK2 激酶 ATP 口袋有效结合,能有效拮抗突变 ALK2 信号传导和成骨分化。OD36 hydrochloride 靶向作用于 ALK2,KD 为 37 nM。 | |||
T74660 |
M4K2234
|
Others | Others |
M4K2234 (compound 26b) 是 ALK2的抑制剂。M4K2234 抑制 ALK2和 ALK5的 IC50值分别为 5 和 2144 nM。M4K2234 可用作 ALK1和 ALK2蛋白激酶的化学探针。M4K2234 可用于癌症的研究。 | |||
T63897 |
LDN193189 Tetrahydrochloride
|
Others | Others |
LDN193189 Tetrahydrochloride 是 BMPI 型受体的选择性抑制剂,能够抑制 ALK2 (IC50: 5 nM) 和 ALK3 (IC50: 30 nM),对 ALK4,ALK5 和 ALK7 的作用效果弱 (IC50≥500 nM)。 | |||
T62783 |
RIPK2-IN-1
|
Others | Others |
RIPK2-IN-1 (compound 18f) 是一种 RIPK2 的有效抑制剂 (IC50: 51 nM),也能够抑制 ALK2 (IC50: 5 nM)。RIPK2-IN-1 在细胞试验中对 RIPK2/NOD2 的 IC50 为 390 nM。 | |||
T6158 |
LDN-193189 HCl
LDN193189 Hydrochloride |
ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
LDN-193189 HCl (LDN193189 Hydrochloride) 是一种选择性 BMP I 型受体激酶抑制剂。 | |||
T84696 |
Itacnosertib (hydrocholide)
TP-0184 (hydrocholide) |
Others | Others |
Itacnosertib hydrocholide为JAK2、ACVR1 (ALK2) 及ALK5的抑制剂。 | |||
T15262 |
Vactosertib Hydrochloride
TEW-7197 Hydrochloride,EW-7197 Hydrochloride |
ALK | Angiogenesis; Tyrosine Kinase/Adaptors |
Vactosertib Hydrochloride is an orally active and ATP-competitive ALK5 inhibitor (IC50: 12.9 nM). It has potently antimetastatic activity and anticancer effect. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC50: 17.3 nM). | |||
T39104 |
Itacnosertib
Itacnosertib,TP-0184 |
Others | Others |
Itacnosertib (TP-0184) is a chemical compound that acts as an inhibitor of JAK2, ACVR1 (ALK2), and ALK5, as indicated in WO2014151871. | |||
T73490 |
MU1700
|
Others | Others |
MU1700 是一种具有口服活性的、强效的 ALK1/2抑制剂,IC50分别为 13 nM 和 6 nM,其具有细胞膜通透性以及高脑渗透性。 | |||
T81410 |
Prafnosbart
DS-6016A |
||
Prafnosbart(DS-6016A)为一种针对ACVR1(Activin A receptor type 1,也称为ACVRLK2,ALK2,ACVR1A,SKR1)的IgG1-kappa型人源化单克隆抗体,适用于骨代谢异常的研究。 | |||
T84919 |
M4K2163 dihydrochloride
|
Others | Others |
M4K2163二盐酸盐是一种高效、选择性的ALK2抑制剂,具有血脑屏障(BBB)渗透能力,IC50为19 nM。该化合物主要用于弥漫性内源性脑桥胶质瘤(DIPG)的研究。 | |||
T81740 |
Multi-kinase-IN-6
|
Trk receptor | Tyrosine Kinase/Adaptors |
Multi-kinase-IN-6 (compound 10e) 是一种效能极高的多激酶抑制剂,具有对 TrkA、ALK2、c-KIT、EGFR、PIM1、CK2α、CHK1 和 CDK2 等多种酶的显著抑制作用。在 MCF7、HCT116 和 EKVX 癌细胞系上,其抗增殖活性突出,IC50 值分别达到 3.36 μM、1.40 μM 与 3.49 μM。此外,Multi-kinase-IN-6 能引起 MCF7 与 HCT116 细胞的细胞周期在 G1/S 期及 G1 期停滞,并有效诱导凋亡。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04774 |
ALK-2/ACVR1 Protein, Human, Recombinant (His)
TSRI,ACVRLK2,FOP,activin A receptor, type I,ACTRI,A... |
Human | Baculovirus Insect Cells |
ALK-2/ACVR1 Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag. The predicted molecular weight is 12.8kDa and the accession number is Q04771. | |||
TMPY-00658 |
ALK-2/ACVR1 Protein, Human, Recombinant (His & hFc)
ALK2,ACVRLK2,ACVR1A,FOP,ACTRI,SKR... |
Human | HEK293 Cells |
ALK-2/ACVR1 Protein, Human, Recombinant (His & hFc) is expressed in HEK293 mammalian cells with His and hFc tag. The predicted molecular weight is 39.6 kDa and the accession number is D3DPA4. | |||
TMPY-01096 |
ALK-2/ACVR1 Protein, Mouse, Recombinant (His & hFc)
Acvr,SKR1,Alk8,D330013D15Rik,ALK2... |
Mouse | HEK293 Cells |
ALK-2/ACVR1 Protein, Mouse, Recombinant (His & hFc) is expressed in HEK293 mammalian cells with His and hFc tag. The predicted molecular weight is 40 kDa and the accession number is P37172. | |||
TMPJ-01158 |
ALK-2/ACVR1 Protein, Human, Recombinant (hFc)
ACVRLK2,FOP,Activin RIA,ACTRI,ALK-2 |
Human | HEK293 Cells |
Activin RIA, also known as ALK-2, TSK-7L, SKR1, TSR-I, and ACTR-I, is a glycosylated 65 kDa type I receptor in the TGF-beta serine/threonine kinase receptor family. Binding of TGF-beta superfamily ligands induces formation of a heterotetrameric complex that contains two chains each of a type I and a type II receptor in multiple combinations. The type II receptors phosphorylate the type I receptors which then phosphorylate and activate Smad signal transduction proteins. Activin RIA functions in a... | |||
TMPJ-01072 |
GALK2 Protein, Human, Recombinant (His)
GalNAc kinase,N-acetylgalactosamine kinase,Galactokinase |
Human | HEK293 Cells |
GALK2 acts as a galactokinase when galactose is present at high concentrations. GALK2 may be involved in a salvage pathway for the reutilization of free GalNAc derived from the degradation of complex carbohydrates. GALK2 has been reported to participate in pathways , such as Amino sugar and nucleotide sugar metabolism, Galactose metabolism and Metabolic pathways. |